Objective: To assess preptin concentrations in pregnant women with and without gestational diabetes mellitus (GDM) and in the cord blood of their fetuses.
Introduction
Gestational diabetes mellitus (GDM) is defined as any degree of glucose intolerance with onset or first recognition during pregnancy. The prevalence may range from 1 to 14% of all pregnancies, depending on the population studied and the diagnostic tests employed. [1] [2] [3] Despite extensive studies, the underlying mechanism of GDM remains elusive. Preptin is a recently isolated 34-amino acid peptide hormone that is cosecreted with insulin from the pancreatic b-cells. 4, 5 Preptin corresponding to Asp 69 -Leu 102 of pro-IGF-IIE peptide is purified from secretory granules isolated from cultured b-cells, along with insulin and amylin. Infusion of preptin into the isolated and perfused rat pancreas exerted a significant increase of the second phase, whereas removal of preptin from the experimental procedure resulted in the reduction of both the first and second phases of insulin secretion. 4 Yang and colleagues recently stated that preptin may have a role in the pathogenesis of type 2 diabetes mellitus by increasing insulin secretion. 6 Buchanan et al. 4 have demonstrated that preptin increases glucose-stimulated insulin secretion but its effects on GDM are unknown. These initial results obtained in previous studies 4, 6 led us to evaluate plasma preptin levels in women with GDM. In this study, we investigated whether maternal serum and cord blood preptin levels are different in women with GDM and non-diabetic pregnant women. We also assessed the association between serum preptin levels and insulin as well as several metabolic parameters in these subjects.
Methods
In all, 31 pregnant women with GDM and 31 gestational age matched pregnant subjects with normal glucose tolerance participated in the study. The subjects were recruited in the Obsterics and Gynecology Department, Inonu University. The study protocol was approved by the Inonu University Medical Faculty Committee for Research on Human Subjects. Informed written consent was obtained from all the subjects/mothers. The normoglycemic pregnant subjects had no family history of type 2 diabetes mellitus, no clinical evidence of any major disease, and were recruited from an unselected population who had undergone routine pregnancy control. Patients with type 1 or type 2 diabetes and patients with macrovascular or microvascular complications, urinary tract infections, urolithiasis, liver cirrhosis, congestive heart failure or other known major diseases were excluded. The pregnant women with GDM were newly diagnosed and had not been treated with oral hypoglycemic agents. None of the control subjects were taking any medication known to alter glucose tolerance. A 50-g glucose loading test was performed for all of the 62 patients who applied between 24th and 28th gestational weeks as recommended by ACOG. 1 A value of 140 mg dl À1 was considered as the cutoff point and all patients with a value >140 mg dl À1 after 50-g glucose loading test underwent 100-g glucose tolerance test to diagnose GDM. Cutoff values for serum glucose were defined as 105, 190, 165 and 145 mg dl À1 for fasting, 1, 2 and 3-h tests after the 100-g glucose tolerance test, respectively. GDM was diagnosed if two or more of the values (venous serum or serum glucose levels) were met or exceeded. Some of the patients with a value of 200 mg dl À1 or higher after 50-g glucose loading test were considered to have GDM and did not undergo 100-g glucose tolerance test. The test was done in the morning after an overnight fast of between 8 and 14 h and after at least 3 days of unrestricted diet (>150 g carbohydrate per day) and unlimited physical activity. The subjects were remained seated and did not smoke throughout the test.
Maternal ages, body mass index (BMI) of the mother at delivery, gestational ages at birth, birth weights, gender, Apgar score, neonatal and maternal complications were the main parameters studied. Cesarean section or spontaneously vaginally delivered newborns were immediately weighed and first/fifth minute Apgar scores were recorded after delivery. Neonates with a birth weight below 10 percentile were defined as small for gestational age and those with a birth weight above 90 percentile were defined as large for gestational age. 4000 g were considered as the cutoff value for the definition of macrosomia. Pregnancy clinical data, fasting preptin, glucose, fasting insulin, blood lipid, homeostasis model assessment index of insulin resistance (HOMA-IR) and perinatal outcomes were investigated. Hypoglycemia was defined as a blood glucose level below 40 mg dl À1 and polycythemia was defined as a venous hematocrit level above 65%. The main clinical and biochemical characteristics of mothers are shown in Table 1 . Anthropometric parameters measured included the height, weight and BMI. The BMI was calculated as weight (kg)/length (m 2 ). All measurements were performed when the patients were in a standing position with joined feet, relaxed abdomen and arms at their sides. BMI was measured as the ratio of the weight to the square of the height. Blood pressure was measured by trained nurses after the subjects had rested for 10 min on the right arm, with the subjects being in a sitting position and relaxed.
Biochemical studies
From each GDM women and control pregnant women, fasting maternal blood was collected from arm vein after cesarean section or vaginal delivery of the baby but before placenta delivery. Cord blood samples were obtained from the umbilical vein immediately after delivery from all GDM and controls. The blood was delivered to the laboratory within 20 min, centrifuged (2000 g ml À1 for 10 min at 4 1C) and the sera aliquoted and stored at À80 1C until assayed. In all GDM and control subjects, fasting serum preptin concentrations were measured by ELISA, with ELx800 Universal Microplate. This assay recognizes natural human preptin concentrations in cell culture supernatants, plasma, serum and other biological fluids. The kit's detection range was 62.5 to 4000 pg ml À1 . The intra-(within day) and inter-assay (between days) coefficients of variation for serum preptin were 3.8 and 10.6%, respectively. Serum insulin levels were measured by competitive chemiluminescent enzyme immunoassay method using the same trademark kits (Immulite 2000 Analyzer, Diagnostic Products Corporation; DPC, Los Angeles, CA, USA). The respective inter-and intra-assay coefficient of variation was 5.7 and 4.3% for insulin. Fasting glucose, triglycerides, total cholesterol and high-density lipoprotein cholesterol concentrations were measured by enzymatic colorimetric assay methods using an Abbott Architect C16000 autoanalyzer (Abbott Diagnostic Laboratories, Chicago, IL, USA) and commercially available kits. The respective inter-and intra-assay coefficient of variation were 3.4 and 3.0% for fasting glucose; 3.2 and 2.7% for triglycerides; 2.7 and 2.4% for total cholesterol and 11.6 and 8.1% for high-density lipoprotein cholesterol. Low-density lipoprotein cholesterol concentrations were calculated using Friedewald formula:
7 LDL-C ¼ TC-HDL-C-TG/5, 
Results
The clinical and biochemical characteristics of our subjects are shown in Table 1 . The difference between groups with regard to maternal age and parity was statistically significant. GDM women had higher HOMA-IR, fasting insulin, 1-h blood glucose after glucose overload than control subjects. The difference between groups with regard to height, weight, BMI, gestational age, birth weight, cord glucose, cord insulin ( Figure 1 ) and blood pressure was statistically insignificant. As lipid profiles were evaluated for each group, the difference between groups was statistically insignificant. Apgar scores of neonates in both groups were evaluated at the first and fifth minutes after birth ( Table 2) . The difference between groups with regard to the first and fifth minute apgar scores was statistically insignificant. The maternal serum preptin levels were found to be higher in patients with GDM compared with controls. The maternal serum preptin levels were significantly higher than the cord blood preptin levels in women with GDM ( Figure 2 ). The cord blood preptin levels of GDM subjects were significantly higher than the cord blood preptin levels in control pregnant women (Figure 3 ). There were no significant differences between male and female newborns in cord blood preptin levels. Preptin concentration in maternal serum was positively correlated with the maternal age, fasting insulin, 1-h blood glucose after glucose overload and cord preptin concentrations at birth (Table 3) . Similarly, cord serum preptin concentrations correlated positively with maternal age, maternal serum preptin, and maternal insulin and 1 h glucose concentrations (Table 4) . Insulin and glucose concentrations in cord serum did not show any relationships with cord serum preptin levels. Maternal serum insulin concentrations correlated positively with HOMA-IR. Pregnancy complications, maternal and fetal morbidity were also evaluated in this study. The differences between groups with regard to the incidences of polyhydramnios were insignificant. Similarly, preeclampsia incidences and cesarean birth rates were similar in both groups. Neonatal complications were the final part of analysis in this study. The differences between groups with regard to the incidences of hospitalization rates, respiratory complications, hyperbilirubinemia, hypoglycemia and polycythemia were insignificant ( Table 5 ). The incidence of small for gestational age babies was the highest in the control group; however, AGA and large for gestational age newborns were similar. Cesarean and vaginal birth rates were similar in each group.
Discussion
In the present study, we found that higher preptin concentrations were observed in GDM mothers and their newborns compared Figure 1 Maternal serum and cord blood insulin levels in GDM and control pregnant women (MS, maternal serum; CB, cord blood; GDM, gestational diabetes mellitus). GDM and maternal serum preptin levels M Aslan et al with respective controls. The upregulation of preptin in the GDM women and their newborns is not clear; it might be the result of either the increased secretion or decreased preptin metabolism. Figure 2 The maternal serum (a) and cord blood preptin (b) levels were found higher in patients with GDM compared with controls. The maternal serum preptin levels were significantly higher than the cord blood preptin levels in women with GDM. GDM women had higher fasting insulin (c) and 1-h blood glucose (d) after glucose overload than control subjects. Data are depicted as box plots with mean (dashed line), median (solid line) and interquartile range. Figure 3 Maternal serum and cord blood preptin levels in GDM and control pregnant women (MS, maternal serum; CB, cord blood; GDM, gestational diabetes mellitus). Table 3 Pearson's correlation coefficients between maternal serum preptin level and measured parameters in GDM subjects (n ¼ 31)
Maternal serum preptin n r P -value Abbreviation: r, correlation coefficients.
GDM and maternal serum preptin levels M Aslan et al
The high concentration of preptin may contribute to insulin secretion. Preptin has been shown to regulate glucose-mediated insulin secretion in normoglycemic and diabetic subjects 4 but these data are limited to ex vivo perfused rat pancreas model. Synthetic rat preptin had a direct effect on the b-cell, enhancing the maximal glucose-stimulated secretion of insulin from cultured bTC6-F7 cells. 4 In our study, we observed a positive correlation between maternal serum insulin concentrations and HOMA-IR in GDM subjects, as well as between maternal serum preptin concentrations and maternal age, cord serum preptin, insulin and 1-h blood glucose after glucose overload. This observation is in agreement with a recent report in which preptin has been found to be correlated with glucose-mediated insulin secretion in perfused rat pancreas. 4 In contrast to our and Buchanan's findings, Yang and colleagues found increased preptin levels in diabetic subjects correlated with elevated insulin resistance (HOMA-IR) but could not demonstrate a significant correlation with insulin secretion. Yang has stated 6 that the difference they found might be because of the species differences and differences in study design. The differences between our observations and Yang's findings may be because Yang has studied for non-pregnant diabetic women but our study concerns GDM subjects.
Interestingly, any clear relationships of maternal and/or cord serum preptin with fetal growth parameters at birth were not detected; however, this does not mean that there is not any role of preptin in with fetal growth. Even though the effects of preptin on proliferation and differentiation of human osteoblasts are reported there is no data about fetal anthropometric and metabolic effects. 9 Yang et al. 6 stated that preptin may have role in the pathogenesis of type 2 diabetes mellitus by increasing insulin secretion. But there is no knowledge about the effect of preptin on fetal growth. Our study showed that high preptin levels in maternal and fetal cord blood does not have an effect on fetal growth. Probably, preptin does not have a role on fetal growth apart from insulin.
Neither the origin of preptin in GDM babies nor the increases of preptin concentration in maternal and cord blood of GDM women are not well understood. As we have observed that the cord blood preptin levels were significantly correlated with maternal serum preptin, it may be possible to speculate that maternal serum preptin levels contribute the majority of cord blood preptin in pregnancy. There are no reports discussing whether maternal preptin cross the placental barrier or not. However, it may be hypothesized that a rise in preptin levels in maternal serum and cord blood seems to be a metabolic response of the fetoplacental unit to gestational diabetes-related hyperglycemia. Another possible explanation is that mother's serum glucose, after it's passage via the fetoplacental barrier, induces the release of preptin from fetal pancreas and, thereby, produces fetal hyperpreptinemia. Inspite of elevation of preptin level, the existence of a normal level of insulin in the cord blood supports our hypothesis that the preptin may be transferred to fetus through placental transfer.
Our study had several limitations including a small sample size and single measurements of preptin during pregnancy. As our analyses are based on single measurements of blood preptin, the results cannot reflect the relationship over time. It would be interesting to measure serial changes of plasma preptin levels in normoglycemic and GDM subjects to further clarify the role of preptin in the pathogenesis of GDM. Further, this is a pilot study powered only to compare preptin levels between these two groups. We were not adequately powered to examine neonatal outcomes. Future studies should focus on both neonatal outcomes and neonatal physiology in relation to maternal preptin levels.
In spite of these limitations, as a first clinical study of preptin and GDM, we were able to detect higher levels of preptin in women with GDM as compared with controls. If these findings could be supported by further studies, then preptin levels may provide a novel approach to identifying women with GDM. Future studies should focus both on the pathophysiology related to the potential interaction of preptin and insulin and on neonatal outcomes. LGA, large for gestational age; SGA, small for gestational age.
